arrow
R

Rohan Garje

Texas Tech University System
H指数:21
被引数:2,872

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer

FOLH1 (PSMA) RNA在原发性和转移性前列腺癌中高表达的分 子与临床相关性

2025-11-110
OA
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

TAR-200联合西特雷利单抗与西特雷利单抗单药治疗作为不适合或拒绝新辅助顺铂为基础化疗的肌层浸润性膀胱癌患者的新辅助治疗(SunRISe-4):一项随机、开放标签Ⅱ期试验的期中分析

2025-08-270
PRE
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
2024-12-020
OAAI
TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)

TAR-200联合西特瑞利单抗(CET)或CET单药作为新辅助疗法,用于不适合或拒绝接受新辅助顺铂为基础化疗(NAC)的肌层浸润性膀胱癌(MIBC)患者的治疗:SunRISe-4(SR-4)研究的中期分析

2024-09-010
PRE
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer
2024-07-171
PRE
Safety Analyses of the Phase 3 VISION Trial of [ 177 Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

[177 Lu]Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的3期视力试验的安全性分析

2024-04-015
OA
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration
2024-02-223
OAAI
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
2021-08-0623
OAAI